In vitro Activation of B-CLL Cells.

Apart from surface Ig receptors, a variety of membrane molecules have now been described to deliver activation and progression signals to human B cells. Among them, CD40 antigen is likely to play a crucial role in the antigen-dependent maturation process. Recent studies performed in the laboratory have established that presentation of anti-CD40 mAbs in a crosslinked fashion by mouse Ltk(-) cells stably expressing human FcyRII/CDw32, allowed normal human B cells to enter into sustained proliferation. In their overwhelming majority, B-CLL cells are positive for CD40 expression. We have therefore examined the capacity of purified B-CLL cells to be stimulated by various cytokines for growth and differentiation, following crosslinking of slgs or CD40 antigen. In most B-CLL specimens studied, IL-2 was the sole factor, among a wide panel of cytokines tested, which reproducibly and significantly induced proliferation of leukemic B cells activated with anti-Ig reagents (SAC or anti-IgM antibodies). Unlike normal B cells, the great majority of anti-Ig activated B-CLL cells failed to proliferate in response to IL-4. In this activation system, IL-4 profoundly suppressed the IL-2 driven proliferation of B-CLL. An opposite pattern of growth-response was obtained following ligation of CD40 since IL-4 elicited proliferation of B-CLL whereas the growth-promoting effect of IL-2 was reduced. Under these culture conditions, IL-4 and IL-2 displayed additive effects on leukemic B cell growth. Surprisingly, IL-4 combined with anti-CD40 mAb allowed activation of certain leukemia specimens otherwise refractory to other stimulatory signals. Most B-CLL samples were induced for IgM synthesis upon SAC stimulation. This Ig response was potentiated by IL-2 and antagonized by IL-4. Anti-CD40 mAb used alone or in combination with cytokines (IL1-IL6, IFNγ, TNFα, TGFβ) failed to induce Ig secretion from B-CLL. No evidence for Ig isotype switching was obtained with the cytokines listed above, whatever the mode of B-CLL activation. Taken together, our results suggest that B-CLL can be released in vitro from their apparent maturation block, by IL-2 and anti-Ig reagents or by IL-4 and immobilized anti-CD40 mAb. Additionally, the data reported here suggest that development of the agonistic and antagonistic activities of IL-4 on B cell growth and differentiation may depend upon the nature of the activation signal provided.

[1]  J. Banchereau,et al.  Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. , 1991, Science.

[2]  J. Ledbetter,et al.  Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. , 1990, Blood.

[3]  P. Galanaud,et al.  Regulatory effects of IL-4 on human B-cell response to IL-2. , 1990, European Cytokine Network.

[4]  A. Barclay,et al.  Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes‐‐a molecule related to nerve growth factor receptor. , 1990, The EMBO journal.

[5]  C. Hivroz,et al.  Altered signal transduction secondary to surface IgM cross-linking on B-chronic lymphocytic leukemia cells. Differential activation of the phosphatidylinositol-specific phospholipase C. , 1990, Journal of immunology.

[6]  J. Banchereau,et al.  4 – Rôle of cytokines in the ontogeny, activation and proliferation of B lymphocytes , 1990 .

[7]  S. Fournier,et al.  Expression of CD23 antigen and its regulation by IL-4 in chronic lymphocytic leukemia. , 1990, Leukemia research.

[8]  G. D. Wetzel Interleukin 5 regulation of peritoneal Ly‐1 B lymphocyte proliferation, differentiation and autoantibody secretion , 1989, European journal of immunology.

[9]  P. Leder,et al.  Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.

[10]  J. Banchereau,et al.  Interleukin (IL) 4 counteracts the helper effect of IL 2 on antigen‐activated human B cells , 1989, European journal of immunology.

[11]  E. Clark,et al.  Structure, function, and genetics of human B cell-associated surface molecules. , 1989, Advances in cancer research.

[12]  J. Banchereau,et al.  Interleukin 4 inhibits the proliferation but not the differentiation of activated human B cells in response to interleukin 2 , 1988, The Journal of experimental medicine.

[13]  A. Carroll,et al.  Bone marrow origin of a B-cell lymphoma , 1988 .

[14]  P. Lipsky,et al.  Inhibitory influence of IL-4 on human B cell responsiveness. , 1988, Journal of immunology.

[15]  J. Banchereau,et al.  Interleukin 4 counteracts the interleukin 2-induced proliferation of monoclonal B cells , 1988, The Journal of experimental medicine.

[16]  R. Hardy,et al.  Normal, autoimmune, and malignant CD5+ B cells: the Ly-1 B lineage? , 1988, Annual review of immunology.

[17]  M. Gobbi,et al.  Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia , 1982, The Journal of experimental medicine.